CRL officer reports equity award share transactions

Charles River Laboratories International, Inc. officer Shannon M. Parisotto reported equity award activity in company stock.

Rhea-AI Filing Summary

Charles River Laboratories International, Inc. officer Shannon M. Parisotto reported equity award activity in company stock. On January 30, 2026, Parisotto acquired 4,236 shares of common stock at $0 per share following the achievement of performance goals under performance share unit awards originally granted on May 26, 2023.

On the same date, 1,067 shares of common stock were disposed of at $211.68 per share, typically reflecting shares withheld to cover taxes. After these transactions, Parisotto directly held 15,184 shares, and indirectly held 982 shares through a revocable trust and 28,510 shares through Karpathos Investments LLC.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Parisotto Shannon M

Role CEVP, Disc & Safety Assessment

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,236	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	1,067	$211.68	$226K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 15,184 shares (Direct); Common Stock — 982 shares (Indirect, By Trust); Common Stock — 28,510 shares (Indirect, by Karpathos Investments LLC)

Footnotes (2)

1. F1. Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023.
2. F2. Reflects the exempt transfer pursuant to Rule 16a-13 of 982 shares held by the reporting person to a revocable trust controlled by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CRL officer Shannon M. Parisotto report?

Shannon M. Parisotto reported two common stock transactions on January 30, 2026. She acquired 4,236 shares at $0 per share from performance share units and had 1,067 shares disposed of at $211.68 per share, typically representing tax withholding on the equity award.

How many Charles River Laboratories (CRL) shares does Shannon M. Parisotto own after this Form 4?

After the reported transactions, Shannon M. Parisotto directly owns 15,184 CRL common shares. She also indirectly holds 982 shares through a revocable trust and 28,510 shares through Karpathos Investments LLC, reflecting her combined reported beneficial ownership structure.

What is the source of the 4,236 CRL shares acquired by Shannon M. Parisotto?

The 4,236 CRL shares were issued at $0 per share upon achieving performance goals in performance share unit awards granted on May 26, 2023. This represents compensation paid in stock rather than a market purchase by the executive.

Why were 1,067 CRL shares disposed of at $211.68 on January 30, 2026?

The 1,067 shares disposed of at $211.68 per share are coded as transaction “F,” typically indicating shares withheld to cover taxes on an equity award. This reduces the executive’s direct holdings while satisfying associated tax obligations in shares.

How are Shannon M. Parisotto’s indirect CRL holdings structured?

Parisotto’s indirect CRL holdings include 982 shares in a revocable trust she controls and 28,510 shares held by Karpathos Investments LLC. These positions are reported as indirect beneficial ownership, reflecting shares held through entities rather than in her name personally.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parisotto Shannon M

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MA 01887

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEVP, Disc & Safety Assessment

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		4,236(1)	A	$0	16,251	D
Common Stock	01/30/2026		F		1,067	D	$211.68	15,184	D
Common Stock								982(2)	I	By Trust
Common Stock								28,510	I	by Karpathos Investments LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023.

2. Reflects the exempt transfer pursuant to Rule 16a-13 of 982 shares held by the reporting person to a revocable trust controlled by the reporting person.

	/s/ Shannon M. Parisotto	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.